Compared with Gilteritinib, an FDA-approved FLT3 inhibitor, our compounds inhibit both FLT3ITD and FLT3-gatekeeper mutations in AML with increased potency, resulting in robust and deeper responses compared with currently available FLT3 inhibitors. This evidence concerns the gene FLT3 and acute myeloid leukemia.